Virtual health assistant for newly diagnosed Black men with prostate cancer
iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men
This study is testing a virtual health assistant to see if it can help Black men who are newly diagnosed with prostate cancer by providing support for their health and emotional needs.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 53 (estimated) |
| Ages | N/A to 80 Years |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Jacksonville, Florida) |
| Trial ID | NCT06535802 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the feasibility and acceptance of a virtual robot assistant model designed to provide support for social determinants of health and psycho-oncology for Black men newly diagnosed with prostate cancer. The study involves five cohorts, including consumer advocates, clinicians, and patients, who will participate in focus groups and surveys to evaluate the intervention's effectiveness. The primary objectives include developing the virtual assistant model and establishing its usability in a urology clinic setting.
Who should consider this trial
Good fit: Ideal candidates for this study are Black men aged 30 to 80 who have been diagnosed with prostate cancer and have abnormal PSA and/or DRE lab values within the last six months.
Not a fit: Patients who are not Black males, those with normal PSA and/or DRE lab values, or those unwilling to consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could enhance support and navigation services for Black men facing prostate cancer, potentially improving their health outcomes.
How similar studies have performed: While this approach is innovative, similar studies have shown promise in utilizing technology for patient support, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * AIM 1: iCCaRE Consortium consumer advocates * Clinicians who are part of the Translational Research \& Clinical Intervention Services (TRaCIS) * AIM 2 ALPHA TESTING: iCCaRE consumer advocates \[2 Community Advisory Board (CAB) and 1 non-CAB\] * AIM 2 BETA TESTING-PATIENTS: * An African American/Black male * A patient who has been diagnosed with prostate cancer in Florida at any time in their life, and/or within the previous 6 months has had an abnormal Prostate-Specific Antigen (PSA) lab value and/or Digital Rectal Examination (DRE) * Minimum age of 30 years old * Consent to participating in the intervention Exclusion Criteria: * AIM 2 BETA TESTING-PATIENTS: * Patients who are not African American/Black males * Patients not diagnosed with prostate cancer in Florida at any time in their life, or within the previous 6 months has not had a normal PSA lab value and/or DRE * Older than 80 years old * Are not willing to consent
Where this trial is running
Jacksonville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Folakemi T. Odedina, PhD — Mayo Clinic
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.